Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients: an Open, Single Arm, Phase II Clinical Trial

NCT05213221 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05213221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05213221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients: an Open, Single Arm, Phase II Clinical Trial
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Completed
Start date
March 14, 2022
Completion date
June 1, 2023
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma